ReviewLeukemia2020
Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.
Review in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.Journal of geriatric oncology · 2020Guideline
- COVID and Cancer: A Complete 3D Advanced Radiological CT-Based Analysis to Predict the Outcome.Cancers · 2023Article
- Immunodiagnosis - the promise of personalized immunotherapy.Frontiers in immunology · 2023Review
- Article
- Article
- Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies.Clinical case reports · 2022Article
- Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.Clinical infection in practice · 2022Article
- Manifestations of COVID-19 infection in children with malignancy: A single-center experience in Jordan.World journal of virology · 2022Article
- Mini Review: Co-Existing Diseases and COVID-19-A One Way Ticket?International journal of environmental research and public health · 2022Review
- Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.Leukemia research · 2021Article
- Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.Oncology letters · 2021Review
- Giant intracardiac thrombosis in an infant with leukaemia and prolonged COVID-19 viral RNA shedding: a case report.Thrombosis journal · 2021Article
- Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.Leukemia · 2021Article
- Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.Frontiers in oncology · 2021Article
- Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services.Frontiers in psychiatry · 2021Article
- SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.British journal of haematology · 2021Article
- Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan.Oncology research and treatment · 2021Article
- Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.Haematologica · 2020Article
- Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.Oncology and therapy · 2020Article
- Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany.Cancer medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.